The researchers used a combination of genomic, transcriptomic, and proteomic analyses to study mechanisms of resistance to the pan-PI3K inhibitor buparlisib.
Called LinkedOmics, the resource features three modules for analyzing multi-omic data collected in projects encompassing 11,158 patients and 32 cancer types.
The organization named the institutions that will be performing the proteomic and proteogenomic analyses planned to for the five-year, $65 million effort.
Researcher Amanda Paulovich will develop multiple-reaction monitoring mass spectrometry assays and apply them to samples from cancer patients in the program.
According to NCI, the MOUs will facilitate the coordination of research and sharing of data and tests for use by scientists and oncologists around the world.
Under the collaboration, University of Victoria researchers will add 2,000 new multiple reaction-monitoring mass spec assays to the CPTAC Assay Portal.
Announced this month, the project brings together CPTAC, the VA, and DoD, and has as its initial goal the proteogenomic analysis of 8,000 lung cancer patients.
The CPTAC study integrated proteomic and genomic data from 77 breast cancer tumors with the aim of identifying potential biomarkers and therapeutic targets.
Among other aims, the five-year effort hopes to use genomic and proteomic data to better understand patient drug response and the development of resistance.
